Microalbuminuria in hypertensive patients: Evaluation of one-year treatment with irbesartan

Kidney International, Supplement

Volumn 67, Issue 93, 2005, Pages

  De Álvaro, Fernando ^a   Velasco, Olga ^b   Honorato, Jesús ^b   Calvo, Carlos ^b   Parrondo, Inma ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE

Author keywords

Hypertension; Irbesartan; Microalbuminuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; ORAL ANTIDIABETIC AGENT; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DEMOGRAPHY; DIABETES MELLITUS; DISEASE MARKER; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; BLOOD CHEMISTRY; CONTROLLED STUDY; KIDNEY FUNCTION; ALBUMINURIA; ALGORITHM; ARTICLE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ALBUMINURIA; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 10944254701     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09307.x     Document Type: Conference Paper

References (18)

1. RITZ E: Albuminuria and vascular damage: The vicious twins. N Engl J Med 348:2349-2352, 2003
2. GERSTEIN HC, MANN JFE, YI Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA 286:421-426, 2001
3. JENSEN JS, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, et al: Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 11:727-732, 1997
4. WACHTELL K, IBSEN H, OLSEN MH, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 139:901, 2003
5. BRAZILAY JI, PETERSON D, CUSHMAN M, et al: The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: The cardiovascular health study. Am J Kidney Dis 44:25-34, 2004
6. RAIJ L: Recommendations for the management of special populations: Renal diseases in diabetes. Am J Hypertens 16:46S-49S, 2003
7. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
8. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 289:2560-2572, 2003
9. GUIDELINES COMMITTEE: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
10. PARVING HH, LEHNER H, BRÖCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
11. LEWIS EJ, HUSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
12. 1999 World Health Organization International Society of Hypertension Guidelines for the management of Hypertension. J Hypertens 17:151-183, 1999
13. AGUIRRE B: Prevalence of microalbuminuria in a hypertensive population of northern Navarra and its relation to other cardiovascular risk factors. Anales Sistema Sanitario de Navarra 27:27-36, 2004
14. BOEKHOLDT SM, PETERS RJ, HACK CE, et al: IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 24:1503-1508, 2004
15. HANSSON L, ZANCHETTI A, CARRUTHERS SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
16. ANDERSEN S, BROCHNER-MORTENSEN J, PARVING HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Diabetes Care 26:3296-302, 2003
17. LINDHOLM LH, IBSEN H, DAHLöF B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:1004-1010, 2002
18. JULIUS S, KJELDSEN SE, WEBER M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363:2022-2031, 2004